Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 10/20 | 0.44 |
| ▸ | CTSD | P07339 | 3/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725305 | 0.95 | DPP4 (0.49) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL29777773 | 0.93 | DPP4 (0.50) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL30591036 | 0.93 | DPP4 (0.52) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL30462198 | 0.93 | DPP4 (0.52) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL30525295 | 0.93 | DPP4 (0.55) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL29377291 | 0.91 | BACE1 (0.51) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL29777726 | 0.91 | BACE1 (0.47) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL30193486 | 0.91 | DPP4 (0.52) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL30575173 | 0.90 | DPP4 (0.43) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL34464998 | 0.89 | DPP4 (0.51) | DPP4DPP8DPP9BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102346-A1 | LIPID COMPOSITION | STEMIRNA THERAPEUTICS CO LTD (CN) | 2026-04-16 | — | — | US | disclosed |
| CN-119654136-A | Lipid composition | 斯微(上海)生物科技股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024032611-A1 | LIPID COMPOSITION | 斯微(上海)生物科技股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| CN-115698295-B | Vaccine reagent and inoculation method | 斯微(上海)生物科技股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115698295-A | Vaccine reagent and inoculation method | 斯微(上海)生物科技股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115427432-A | Vaccine agent for treating or preventing coronavirus disease mutant strain | 斯微(上海)生物科技股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022233287-A1 | VACCINE REAGENT AND VACCINATION METHOD | 斯微(上海)生物科技股份有限公司 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022171182-A1 | VACCINE REAGENT FOR TREATING OR PREVENTING CORONAVIRUS MUTANT STRAIN | 斯微(上海)生物科技股份有限公司 | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102346-A1 | LIPID COMPOSITION | LIPC, PLIN3, CETP | DPP4 3151/4885DPP8 1879/4885DPP9 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.